Effect of age on the pharmacokinetics and pharmacodynamics of flunixin meglumine following intravenous and transdermal administration to Holstein calves

Abstract

OBJECTIVE To determine the effect of age on the pharmacokinetics and pharmacodynamics of flunixin meglumine following IV and transdermal administration to calves. ANIMALS 8 healthy weaned Holstein bull calves. PROCEDURES At 2 months of age, all calves received an injectable solution of flunixin (2.2 mg/kg, IV); then, after a 10-day washout period, calves received a topical formulation of flunixin (3.33 mg/kg, transdermally). Blood samples were collected at predetermined times before and for 48 and 72 hours, respectively, after IV and transdermal administration. At 8 months of age, the experimental protocol was repeated except calves received flunixin by the transdermal route first. Plasma flunixin concentrations were determined by liquid chromatography-tandem mass spectroscopy. For each administration route, pharmacokinetic parameters were determined by noncompartmental methods and compared between the 2 ages. Plasma prostaglandin (PG) E concentration was determined with an ELISA. The effect of age on the percentage change in PGE concentration was assessed with repeated-measures analysis. The half maximal inhibitory concentration of flunixin on PGE concentration was determined by nonlinear regression. RESULTS Following IV administration, the mean half-life, area under the plasma concentration-time curve, and residence time were lower and the mean clearance was higher for calves at 8 months of age than at 2 months of age. Following transdermal administration, the mean maximum plasma drug concentration was lower and the mean absorption time and residence time were higher for calves at 8 months of age than at 2 months of age. The half maximal inhibitory concentration of flunixin on PGE concentration at 8 months of age was significantly higher than at 2 months of age. Age was not associated with the percentage change in PGE concentration following IV or transdermal flunixin administration. CONCLUSIONS AND CLINICAL RELEVANCE In calves, the clearance of flunixin at 2 months of age was slower than that at 8 months of age following IV administration. Flunixin administration to calves may require age-related adjustments to the dose and dosing interval and an extended withdrawal interval.

Evaluation of the pharmacokinetics and efficacy of transdermal flunixin for pain mitigation following castration in goats

“…An additional explanation for the lack of PGE 2 reduction in the current study may also be the lower bioavailability of TD FM in goats (24.76%) as reported by Reppert et al (2019) . Lack of PGE 2 suppression may also be associated with age as demonstrated in calves, perhaps indicating a greater half maximal inhibitory concentration for young goats ( Kleinhenz et al, 2018a ). Further research with greater sample sizes and more frequent sample collection are warranted to determine varying flunixin effects on PGE 2 following painful stimuli in an in vivo model.…”

Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in alpacas

“…Prostaglandin E 2 inhibition has been used as a measure to determine efficacy of flunixin meglumine in several species (Kleinhenz et al, ; Königsson, Törneke, Engeland, Odensvik, & Kindahl, ; Reppert et al, ). In this study, PGE 2 inhibition was quantified for both IV and TD flunixin meglumine formulations.…”

“…Plasma PGE 2 concentrations were determined using methods adapted from Fraccaro et al () and Kleinhenz et al () (Reppert et al, ). Briefly, 1 ml of blood was collected from samples collected before drug administration and at 1, 2, 4, 12, 24 and 48 hr postdrug administration prior to centrifugation.…”

Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in meat goats

“…() and Kleinhenz et al. (). Briefly, 1 ml of blood was obtained from samples collected before drug administration and at 1, 2, 4, 12, 24, and 48 hr post‐drug administration prior to centrifugation.…”